The ‘Abilify’ injection will be adopted in the domestic market
A long-acting injection product that has attracted the schizophrenia field will be adopted.
According to the industry concerned on the 10th, Korea Otsuka Pharmaceuticals is getting ready to turn in a new drug application to get an approval for the schizophrenia treatment ‘Abilify (aripiprazole)’...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
